Allergy Therapeutics Outlook Confident As Revenue Rises In First Half
Allergy Therapeutics Outlook Confident As Revenue Rises In First Half
Read moreMon, 10th Oct 2016 11:59
Allergy Therapeutics Outlook Confident As Revenue Rises In First Half
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.
Read moreAllergy Therapeutics Looking To Chinese Market As It Swings To Profit
Read more(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.
Read more(Alliance News) - Allergy Therapeutics PLC on Wednesday said it has appointed Mary Tavener as a non-executive director with immediate effect.The biotechnology company said Tavener has in 19
Read moreLONDON (Alliance News) - Allergy Therapeutics PLC on Monday said its Acarovac MPL vaccine improved dust mite allergy symptoms during a phase one study.The AM101 study, which was open-label
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous 'Acarovac MPL' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following a successful round of meetings with German and American regulatory bodies.
Read moreLONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - Tinto, up 2.3%, Group, up in
Read moreLONDON (Alliance News) - Allergy Therapeutics PLC on Monday said a phase three trial of its birch pollen allergy vaccine did not meet its primary endpoint.Shares in Allergy Therapeutics 43%
Read more(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of its new adjuvanted birch allergoid product.
Read moreLONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday reported significantly higher profit for the first six months of its financial year as revenue rose and research costs were the to of
Read more(Sharecast News) - Specialty pharmaceutical group Allergy Therapeutics announced its unaudited interim results for the six months ended 31 December on Wednesday, reporting a 10.6% improvement in revenue on both a reported and constant currency basis, to £46.7m.
Read moreLONDON (Alliance News) - Allergy immunology vaccines developer Allergy Therapeutics PLC said Wednesday trading in the first half was in line with expectations.Allergy Therapeutics expects -
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market for the six months ended 31 December on Wednesday, reporting that it was trading in line with board expectations.
Read more